Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Postoperative Neurocognitive Disorders in Elderly Patients
NCT05613491Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of Generex Oral-lyn in Postoperative neurocognitive disorder (PND) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Incidence of postoperative delirium. Status: unknown.
02
Drugs
Generex Oral-lyn
03
Conditions
Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on NCT05613491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613491.